Tenax Therapeutics (TENX) Asset Writedowns and Impairment (2011 - 2016)

Tenax Therapeutics has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $33.3 million in Q4 2016.

• Asset Writedowns and Impairment for Q4 2016 came in at $33.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2016 was $33.3 million (changed N/A YoY), and the FY2016 annual result was $33.3 million, up 3114.44% from the prior year.
• Asset Writedowns and Impairment grew to $33.3 million in Q4 2016, from $24110.0 in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $33.3 million in Q4 2016 and troughed at $24110.0 in Q2 2013.
• A 3-year average of $8.4 million and a median of $60423.5 in 2012 frame the typical range for Asset Writedowns and Impairment.
• The widest annual swing landed in 2012, when Asset Writedowns and Impairment sank 90.81%; it then slipped 13.14% in 2013.
• A 3-year view of Asset Writedowns and Impairment shows it stood at $27758.0 in 2012, then declined by 13.14% to $24110.0 in 2013, then surged by 137872.21% to $33.3 million in 2016.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $33.3 million in Q4 2016, $24110.0 in Q2 2013, and $27758.0 in Q2 2012.